Application progress of 18F-FDG PET-CT in chimeric antigen receptor T-cell therapy for B-cell lymphoma

VernacularTitle:18F-FDG PET-CT在嵌合抗原受体T细胞治疗B细胞淋巴瘤中的应用研究进展
Author: Jianchang QI ¹ ; Yutao YAN ; Shuo ZHANG
Author Information

1. 联勤保障部队第九八八医院放射诊断科，郑州　450007
Keywords: 18F-FDG PET-CT; Chimeric antigen receptor T-cell; B-cell lymphoma
From: Journal of Leukemia & Lymphoma 2024;33(6):377-380
CountryChina
Language:Chinese
Abstract: In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has shown a certain value in the treatment of malignant hematological tumors, especially for patients with relapsed/ refractory B-cell lymphoma. Currently, 18F-FDG PET-CT has proved its great clinical values in the diagnosis and treatment of lymphoma. There are relatively few studies using 18F-FDG PET-CT to evaluate B-cell lymphoma treated by CAR-T therapy, but some good results have also been achieved. This paper reviews the current research progress of 18F-FDG PET-CT in CAR-T therapy for B-cell lymphoma.